IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2026)

IDEAYA Biosciences (IDYA) reported EBT Margin of 3548.25% for Q1 2026, down 308.56% sequentially from 868.47% in Q4 2025.

IDEAYA Biosciences (IDYA) EBT Margin (2020 - 2026) Analysis & Trends

IDEAYA Biosciences (IDYA) has 7 years of EBT Margin data on file, last reported at 3548.25% in Q1 2026.

For the quarter ending Q1 2026, EBT Margin changed N/A year-over-year to 3548.25%; the trailing twelve-month figure through Mar 2026 stood at 186.2% (changed N/A YoY), and the FY2025 full-year result was 161.98%, up 686089.0% from the prior year.
EBT Margin retreated to 3548.25% in Q1 2026, from 868.47% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 14.51% in Q3 2025 to a low of 3548.25% in Q1 2026.
A 5-year average of 897.66% and a median of 638.92% in 2022 frame the typical range for EBT Margin.
Across the five-year window, EBT Margin sank 110492 bps in 2024 and soared 123527 bps in 2025, its largest moves.
Tracing IDYA's EBT Margin over 5 years: stood at 629.69% in 2022, then plunged by 59 bps to 998.83% in 2023, then sank by 111 bps to 2103.74% in 2024, then surged by 59 bps to 868.47% in 2025, then slumped by 309 bps to 3548.25% in 2026.
Business Quant data shows IDYA's EBT Margin at 3548.25% in Q1 2026, 868.47% in Q4 2025, and 14.51% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	17.13%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	41.95%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	23.05%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	34.77%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	IDEAYA Biosciences	3.21 Bn	2.54 Bn	-	-3,548.25%

Download Data